[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-nephropathy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100611469","phase-1-mesenchymal-stem-cells-for-chronic-kidney-diseases-100611469",false,"NCT07240987","Mesenchymal Stem Cells for Chronic Kidney Diseases","A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases","Inclusion Criteria:\n\n* Agreement to participate in the trial and provision of signed written informed consent\n* Pathological diagnosis of diabetic nephropathy or hypertensive renal damage\n* 15 ≤ eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m², UACR \\> 300 mg\u002Fg\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Extremely severe anemia (hemoglobin \\\u003C 30 g\u002FL)\n* Received blood product transfusion therapy within 1 month\n* Autosomal dominant or recessive polycystic kidney disease (ADPKD)\n* History of kidney transplant or other solid organ transplant\n* Active systemic or localized infection (e.g., pneumonia, osteomyelitis)\n* Allergy to stem cells themselves or stem cell-related culture medium\n* History of allergic reaction to cell products (e.g., blood transfusion, platelets)\n* History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)\n* History of malignancy or current malignant disease\n* Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)\n* Pregnant women or women with plans for pregnancy within 3 months after MSC therapy\n* Participation in drug-related clinical trials within the past 2 months\n* Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.",[27,28,29],"Kidney Disease, Chronic","Diabetic Kidney Disease (DKD)","Hypertensive Nephropathy","NOT_YET_RECRUITING","2025-12-18",{"date":33,"type":34},"2025-12-24","ACTUAL",{"date":36,"type":20},"2026-01-01",{"date":38,"type":20},"2027-08-31",{"name":40,"class":41},"The First Affiliated Hospital of Air Force Medicial University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100607373","phase-4-ace-reno-pico-cell-matrix-and-its-effect-on-egfr-in-chronic-kidney-diseases-100607373","NCT07187713","ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases","ACE Reno, Effect of Pico Cell Matrix on Patients With Micro-albuminuria, Proteinuria or CKD (of Any Degree) Due to Diabetes Mellitus, Autoimmune, Miscellaneous Aetiology","ACE Reno","Inclusion Criteria:\n\n* Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi\u002FARB, SGLT2i, or MRA allowed.\n\nExclusion Criteria:\n\n* Recent kidney transplant (\\\u003C12 months). Uncontrolled acute infection or unstable autoimmune disease. Pregnancy or lactation. Known hypersensitivity to study components.","80 Years",{"count":52,"type":20},300,[54],"PHASE4","This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria\u002Fproteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux\u002FUTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-transplant proteinuria.\n\nNephropathy remains a global health burden, with \\~9-10% of the population affected by chronic kidney disease (CKD), equating to \\>750 million individuals worldwide. The socioeconomic costs are substantial: in England CKD costs \\~£7 billion annually, projected to rise to \\~£14 billion by 2033; in Malaysia, prevalence rose from 9% to 15.5% within 7 years; in Egypt, CKD imposes heavy familial and financial burdens, especially for pediatric patients; in Turkey, CKD is among the top causes of disability, linked to the rising tide of diabetes, obesity, and hypertension.\n\nACE Reno is designed to address multiple drivers of CKD progression - glomerulosclerosis, fibrosis, endothelial dysfunction, and maladaptive RAAS\u002Faldosterone signaling - through its peptide components that mimic antifibrotic (BMP-7, HGF, Klotho-like) and vasodilatory\u002FcGMP-mediated (natriuretic peptide-like) pathways.",[29,57,58,59,60,61,62,63],"Auto Immune Disorders","Chronic Kidney Disease","Chronc Kidney Disease Stage 5","Chronic Kidney Disease (Stage 3-4)","Chronic Kidney Disease (Stages 4 and 5)","Microalbuminuria","Diabetic Nephropathies",[65,66,67],"chronic kidney disease","ckd","nephropathy","RECRUITING","2025-09-19",{"date":71,"type":34},"2025-09-23",{"date":73,"type":20},"2025-09-20",{"date":75,"type":20},"2026-12-31",{"name":77,"class":78},"Ace Cells Lab Limited","INDUSTRY",1]